Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial

J. Lacour, F. Lacour, A. Spira, M. Michelson, J. Y. Petit, G. Delage, D. Sarrazin, G. Contesso, J. Viguier

Research output: Contribution to journalArticlepeer-review

Abstract

The results of a randomised trial of polyadenylic-polyuridylic acid given as an adjuvant treatment for operable breast cancer were reviewed after a mean follow up period of 87 months. Of the 300 patients included in the original trial, 145 had been allocated to conventional treatment alone and served as controls. At the time of review the overall survival of the group given polyadenylic-polyuridylic acid was significantly improved (p <0.05) as compared with that of the controls given conventional treatment alone. Significant benefit (p <0.02) was also observed among patients with evidence of disease in lymph nodes, the best results occurring in those with up to three invaded nodes, who showed a significant increase in both overall and relapse free survival. No evidence of toxicity was recorded. These findings confirm the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Results in an experimental model and in patients receiving the adjuvant suggested a possible role of interferon and natural killer (NK) cells in the mechanism of action.

Original languageEnglish
Pages (from-to)589-592
Number of pages4
JournalBritish Medical Journal
Volume288
Issue number6417
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: Updated results of a randomised trial'. Together they form a unique fingerprint.

Cite this